

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Supplemental Table 4. Anti-drug antibody epitope specificity analysis

Cohort (mg)	Visit	Mean Tier 2 Percent Inhibition, (%)		
		TIM-3/PD-L1 (LY3415244)	Anti-TIM-3 Ab (C22)	Anti-PDL1 Ab (ABC110)
A1 (3)	C1D1 (Day 1)	36	34	12
	C1D15 (Day 14)	46	44	6
	C2D1 (Day 28)	87	41	54
	Day 83	100	59	47
A2 (10)	C1D1 (Day 1)	20	15	3
	C1D15 (Day 14)	28	21	11
	C2D1 (Day 28)	85	65	59
	C3D1 (Day 58)	97	45	79
A3 (30)	C1D1 (Day 1)	42	19	29
	C1D15 (Day 14)	93	89	12
	C2D1 (Day 28)	99	91	25
	C3D1 (Day 58)	100	89	37
A4 (70)	C1D1 (Day 1)	33	28	5
	C1D15 (Day 14)	100	84	63
	IRR Kit (Day 29)	100	76	61
	IRR Kit (Day 36)	100	73	59

Abbreviations: Ab, antibody; C, cycle; D, day; IRR, infusion-related reaction; PD-L1, programmed death ligand 1; IRR, infusion-related reaction; TIM-3, T cell immunoglobulin and mucin-domain-containing molecule-3.

Note: IRR kit contains blood collection tubes to assess antidrug antibodies. Drug concentration and may be analyzed for exploratory hypersensitivity markers of basophil/mast cell activation (e.g., tryptase), immune complex formation (e.g., C3 levels), and cytokine release (e.g., IL-6) as appropriate for the clinical presentation.